CD274 and neoplasm: In recent years, immune checkpoint inhibitor therapy has shown great promise as a treatment for several cancers 10-12, and a few trials employed immunohistochemical (IHC) staining of PD-L1 (programmed death-ligand 1) on tumor cells and/or immune cells as a predictive biomarker to separate responders from non-responders 13, 14.